TrimRX
US$ 25.53
glp 1 receptor agonists for type 2 diabetes Clinical Focus on GLP-1 in Mellitus GLP-1 receptor agonists are increasingly
Description
Repurposing anti-diabetic drugs for the treatment of Parkinson's disease: Rationale and clinical experience
These results are in alignment with those of Mitchell et al
Sbeit W, Khoury T
(4) Obesity rates were under 10% in the 1950s
In a randomised controlled trial with over 1800 participants comparing tirzepatide to semaglutide, the tirzepatide group reported more serious adverse events (5-7% VS 3%) and higher discontinuation rates due to adverse events (6-8.5% VS 4%)
Financial analysts like Goldman Sachs project that the global market for these drugs could soar to $95 billion by 2030
